Whitehawk Therapeutics, Inc. Asset Resilience Ratio
Whitehawk Therapeutics, Inc. asset resilience ratio. Whitehawk Therapeutics, Inc. (WHWK) has an Asset Resilience Ratio of 74.64% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See WHWK cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Whitehawk Therapeutics, Inc. (2021–2024)
Asset resilience ratio of Whitehawk Therapeutics, Inc. from 2021 to 2024. This chart shows how Whitehawk Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read WHWK total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Whitehawk Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Whitehawk Therapeutics, Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $124.67 Million | 74.64% |
| Total Liquid Assets | $124.67 Million | 74.64% |
Asset Resilience Insights
- Very High Liquidity: Whitehawk Therapeutics, Inc. maintains exceptional liquid asset reserves at 74.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Whitehawk Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Whitehawk Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Whitehawk Therapeutics, Inc. Asset Resilience Ratio by Year (2021–2024)
Whitehawk Therapeutics, Inc. asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Whitehawk Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 26.40% | $18.57 Million | $70.32 Million | -8.30pp |
| 2023-12-31 | 34.70% | $45.96 Million | $132.42 Million | -37.78pp |
| 2022-12-31 | 72.48% | $133.54 Million | $184.24 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $157.91 Million | -- |
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more